Merck claims a brace of head and neck cancer approvalsMerck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals Share XMerck claims a brace of head and neck cancer approvalshttps://pharmaphorum.com/news/merck-claims-a-brace-of-head-and-neck-cancer-approvals/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Keytruda gets okay from FDA for adjuvant melanomaThe US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who Share XKeytruda gets okay from FDA for adjuvant melanomahttps://pharmaphorum.com/news/keytruda-gets-okay-from-fda-for-adjuvant-melanoma/
Keytruda combo set to become “standard of care” in kidney cancerAnalysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care Share XKeytruda combo set to become “standard of care” in kidney cancerhttps://pharmaphorum.com/news/keytruda-combo-set-to-become-standard-of-care-kidney-cancer/
Keytruda cuts risk of death by 31% in esophageal cancer trialMSD’s Keytruda has cut the risk of death by 31% in patients with esophageal or esophagogastric junction carcinoma Share XKeytruda cuts risk of death by 31% in esophageal cancer trialhttps://pharmaphorum.com/news/keytruda-cuts-risk-of-death-by-31-in-esophageal-cancer-trial/
Merck bags adjuvant okay for Keytruda in melanomaCheckpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval Share XMerck bags adjuvant okay for Keytruda in melanomahttps://pharmaphorum.com/news/merck-bags-adjuvant-okay-for-keytruda-in-melanoma/
Merck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKMerck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in Share XMerck & Co’s cancer blockbuster Keytruda funds cutting edge rare disease R&D in UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/merck-cancer-blockbuster-keytruda-funds-rare-disease/
Merck gets FDA okay for Keytruda as liver cancer therapyMerck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular Share XMerck gets FDA okay for Keytruda as liver cancer therapyhttps://pharmaphorum.com/news/merck-gets-fda-okay-for-keytruda-as-liver-cancer-therapy/
Keytruda approved for combination lung cancer therapyThe US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line Share XKeytruda approved for combination lung cancer therapyhttps://pharmaphorum.com/news/keytruda-approved-for-combination-lung-cancer-therapy/
